# Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

> **NCT00169143** · PHASE2 · COMPLETED · sponsor: **Lymphoma Study Association** · enrollment: 60 (—)

## Conditions studied

- Untreated CD20-positive Large B-cell Lymphoma

## Interventions

- **DRUG:** Rituximab + ACVBP regimen plus Pegfilgrastim
- **PROCEDURE:** Autologous stem cell transplant

## Key facts

- **NCT ID:** NCT00169143
- **Lead sponsor:** Lymphoma Study Association
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 60 (—)
- **Last updated:** 2018-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00169143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00169143, "Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00169143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*